title: Recent advances with recombinant bacterial vaccine vectors.
abstract: Bacille Calmette-Guerin (BCG), Listeria monocytogenes, Salmonellae and Shigellae have shown promise as vaccine vectors in experimental animal models. Although disappointing results in humans and non-human primates stalled the development of this vaccination strategy, interest in this approach was reinvigorated recently by the development of bacterial DNA-vaccine-vectors. The purpose of this review is to highlight the strengths and weaknesses of bacterial vaccine vectors, and to discuss the future prospects of these vaccine delivery systems.
authors.affiliation: Division of Vaccine Research, Institute of Human Virology, 725 Lombard Street, Baltimore, MD 21201, USA.
authors.forename: M T
authors.initials: MT
authors.lastname: Shata
authors.forename: L
authors.initials: L
authors.lastname: Stevceva
authors.forename: S
authors.initials: S
authors.lastname: Agwale
authors.forename: G K
authors.initials: GK
authors.lastname: Lewis
authors.forename: D M
authors.initials: DM
authors.lastname: Hone
mesh_terms: D000818:Animals; D000941:Antigens / Q000235:genetics / Q000276:immunology; D001500:BCG Vaccine / Q000235:genetics / Q000276:immunology; D001428:Bacterial Vaccines / Q000235:genetics* / Q000276:immunology* / Q000627:therapeutic use; D005822:Genetic Vectors; D006801:Humans; D008089:Listeria monocytogenes / Q000235:genetics / Q000276:immunology; D012475:Salmonella / Q000235:genetics / Q000276:immunology; D012760:Shigella / Q000235:genetics / Q000276:immunology; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000235:genetics* / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D000941:Antigens; D001500:BCG Vaccine; D001428:Bacterial Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic